Which stocks in any sector do Indian mutual fund managers prefer most? — June 2026 data
| # | Stock Name | No. of MFs Holding | Avg Weight (%) | Total MF Value (Cr) |
|---|---|---|---|---|
| 21 | Acutaas Chemicals Ltd | 130 funds | 3.39% | ₹3,775 Cr |
| 22 | Neuland Laboratories Limited | 117 funds | 1.73% | ₹2,991 Cr |
| 23 | GlaxoSmithKline Pharmaceuticals Limited | 112 funds | 0.70% | ₹1,987 Cr |
| 24 | Cohance Lifesciences Limited | 101 funds | 0.94% | ₹3,138 Cr |
| 25 | Piramal Pharma Limited | 93 funds | 1.21% | ₹2,951 Cr |
| 26 | Eris Lifesciences Limited | 89 funds | 1.16% | ₹3,693 Cr |
| 27 | Onesource Specialty Pharma Limited | 84 funds | 1.63% | ₹2,447 Cr |
| 28 | Wockhardt Limited | 83 funds | 1.84% | ₹2,153 Cr |
| 29 | Granules India Limited | 81 funds | 2.19% | ₹709 Cr |
| 30 | Natco Pharma Limited | 81 funds | 1.07% | ₹320 Cr |
| 31 | Pfizer Limited | 76 funds | 1.06% | ₹2,468 Cr |
| 32 | Emcure Pharmaceuticals Limited | 70 funds | 0.99% | ₹2,377 Cr |
| 33 | Jubilant Pharmova Limited | 62 funds | 1.17% | ₹1,107 Cr |
| 34 | Concord Biotech Limited | 57 funds | 0.71% | ₹540 Cr |
| 35 | Caplin Point Laboratories Limited | 56 funds | 0.81% | ₹371 Cr |
| 36 | Blue Jet Healthcare Ltd | 45 funds | 0.39% | ₹157 Cr |
| 37 | SANOFI CONSUMER HEALTHCARE | 41 funds | 0.59% | ₹1,388 Cr |
| 38 | Corona Remedies Limited | 37 funds | 0.92% | ₹1,502 Cr |
| 39 | Rubicon Research Limited | 34 funds | 1.58% | ₹1,671 Cr |
| 40 | Alembic Pharmaceuticals Limited | 29 funds | 0.69% | ₹1,372 Cr |
The table above ranks the top 20 stocks in the Pharmaceuticals & Biotechnology sector by the number of Indian mutual fund schemes holding them as of June 2026. When a large number of fund managers independently choose the same stock, it is a powerful signal of institutional conviction — these are the stocks that professional money managers believe in most.
A stock held by 200+ mutual funds means that hundreds of fund managers — each doing their own independent research — have concluded that this stock deserves a place in their portfolio. This collective wisdom is one of the most reliable indicators of a stock's quality within its sector. The average weight shows how much of their portfolio each fund typically allocates to the stock, and the total MF value shows the combined rupee investment across all funds holding it.
All data is sourced from monthly portfolio disclosures that every AMFI-registered mutual fund is required to publish. RightAdvise compiles and analyses this data across 1,100+ active fund schemes to give you a clear, unbiased view of where professional fund managers are investing in the Pharmaceuticals & Biotechnology sector. Click any stock name in the table to see which specific funds hold it and in what proportion.